1-8 of 8
Pablo Rendo, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Zinc Finger Nuclease-Mediated Disruption of the BCL11A Erythroid Enhancer Results in Enriched Biallelic Editing, Increased Fetal Hemoglobin, and Reduced Sickling in Erythroid Cells Derived from Sickle Cell Disease Patients

Samuel Lessard, PhD, Pauline Rimmele, PhD, Hui Ling, PhD, Kevin Moran, MSc, Benjamin Vieira, BS, Yi-Dong Lin, PhD, Vu Hong, PhD, Andreas Reik, PhD, Denny Dang, Naoya Uchida, MD, John F. Tisdale, MD, Pablo Rendo, MD, Ahmed Daak, PhD, Alexandra Hicks, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 974.
https://doi.org/10.1182/blood-2019-126048
Published: 2019
Journal Articles

Impact of Treatment Regimen with Moroctocog Alfa (AF-CC) on Bleeding Frequency in Pediatric Aged Subjects with Moderately Severe to Severe Hemophilia A

Mark P. Smith, MD FRACP, FRCPA, Jeremy Rupon, MD, Yasser Wali, MD, Hala Remawi, MD, Joan Korth-Bradley, PharmD, PhD, Lynne Smith, MBA, Pablo Rendo, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1205.
https://doi.org/10.1182/blood-2018-99-111891
Published: 2018
Journal Articles

An Open-Label Study of the Safety and Efficacy of Morotocog Alfa (AF-CC) in Previously Untreated Patients Aged <6 Years in Usual Care Settings

Kaan Kavakli, MD, James Baumann, Francois Pierre Huard, MS, MBA, Lynne Smith, MBA, Christine Alvey, Joan Korth-Bradley, PharmD, PhD, Pablo Rendo, MD, Jeremy Rupon, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1091.
https://doi.org/10.1182/blood.V130.Suppl_1.1091.1091
Published: 2017
Journal Articles

Nonacog Alfa: Analysis Of Safety Data From 6 Prospective Clinical Studies In Different Patient Populations With Hemophilia B Treated With Different Therapeutic Modalities

Pablo Rendo, MD, Lynne Smith, MBA, Lee Hsiao-Yu, Frank E. Shafer, MD
Journal: Blood
Blood (2013) 122 (21): 3604.
https://doi.org/10.1182/blood.V122.21.3604.3604
Published: 2013
Journal Articles

Lack of Seasonal Variation in Bleeding and Patient-Assessed Pain Patterns in Patients with Hemophilia B Receiving On-Demand Therapy

Frank E. Shafer, MD, Lynne Smith, MBA, Nicholas Vendetti, MS, Pablo Rendo, MD, Marcus E. Carr, MD
Journal: Blood
Blood (2012) 120 (21): 1136.
https://doi.org/10.1182/blood.V120.21.1136.1136
Published: 2012
Journal Articles

Evaluation of Two Secondary Prophylaxis Regimens of Recombinant Factor IX(r-IX) in Moderately Severe to Severe( FIX ≤2%) Hemophilia B Patients

Pablo Rendo, MD, Mary-Kate Barrette-Grischow, MA, MPH, Lynne Smith, MBA, JM Korth-Bradley, Robert Charnigo, Frank E. Shafer, MD
Journal: Blood
Blood (2012) 120 (21): 4628.
https://doi.org/10.1182/blood.V120.21.4628.4628
Published: 2012
Journal Articles

Pharmacokinetic/Pharmacodynamic Assessment of Reformulated Recombinant Coagulation Factor IX in Adults and Children with Severe Hemophilia B

JM Korth-Bradley, Leonard A. Valentino, MD, FAAP, Pablo Rendo, MD, Frank E. Shafer, MD, Lynne Smith, James A. Baumann, Robert Charnigo
Journal: Blood
Blood (2011) 118 (21): 1190.
https://doi.org/10.1182/blood.V118.21.1190.1190
Published: 2011
Journal Articles

Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients: Results From a Prospective Registry of European Hemophilia B Patients.

Pablo Rendo, MD, Erik Berntorp, MD, PhD, David M. Keeling, MD, Michael Makris, MD, Cedric R. Hermans, MD., PhD., Ereline Pauline Mauser-Bunschosten, Roberto Musso, Annarita Tagliaferri, Carl Kollmer, James Baumann, Robert Charnigo
Journal: Blood
Blood (2010) 116 (21): 3664.
https://doi.org/10.1182/blood.V116.21.3664.3664
Published: 2010